Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 25;181(7):1458-1463.
doi: 10.1016/j.cell.2020.05.041. Epub 2020 May 27.

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

Gregory D Sempowski  1 , Kevin O Saunders  2 , Priyamvada Acharya  2 , Kevin J Wiehe  3 , Barton F Haynes  4
Affiliations
Review

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

Gregory D Sempowski et al. Cell. .

Abstract

The SARS-CoV-2 pandemic that causes COVID-19 respiratory syndrome has caused global public health and economic crises, necessitating rapid development of vaccines and therapeutic countermeasures. The world-wide response to the COVID-19 pandemic has been unprecedented with government, academic, and private partnerships working together to rapidly develop vaccine and antibody countermeasures. Many of the technologies being used are derived from prior government-academic partnerships for response to other emerging infections.

Keywords: ▪▪▪.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests B.F.H. and G.D.S. have a patent submitted for the emerging infections preparedness platform and influenza antibodies (No. 62_902705).

Figures

Figure 1
Figure 1
Schema of Iterative and Synergistic Approaches Being Used to Simultaneously Develop Both Vaccines and Antibody Countermeasures for SARS-CoV-2/COVID-19
Figure 2
Figure 2
Accelerated Platform Technology for Rapid B Cell Screening and Isolation of Pathogen Neutralizing Antibodies Being Used to Isolate SARS-CoV-2 Antibodies
See this image and copyright information in PMC

References

    1. Andreano E., Nicastri E., Paciello I., Pileri P., Manganaro N., Piccini G., Manenti A., Pantano E., Kabanova A., Troisi M. Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients. bioRxiv. 2020 doi: 10.1101/2020.05.05.078154. - DOI - PMC - PubMed
    1. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011;481:81–84. - PMC - PubMed
    1. Bao L., Deng W., Huang B., Gao H., Liu J., Ren L., Wei Q., Yu P., Xu Y., Qi F. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 doi: 10.1038/s41586-020-2312-y. - DOI - PubMed
    1. Bill & Melinda Gates Foundation . 2020. Press Release: COVID-19 Therapeutics Accelerator Awards $20 Million in Initial Grants to Fund Clinical Trials.
    1. Bolles M., Deming D., Long K., Agnihothram S., Whitmore A., Ferris M., Funkhouser W., Gralinski L., Totura A., Heise M., Baric R.S. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011;85:12201–12215. - PMC - PubMed

MeSH terms

LinkOut - more resources